Abstract
Context The COVID-19 pandemic response has demonstrated the interconnectedness of individuals, organizations, and other entities jointly contributing to the production of community health. This response has involved stakeholders from numerous sectors who have been faced with new decisions, objectives, and constraints.
Objective We aimed to examine the cross-sector organizational decision landscape that formed in response to the COVID-19 pandemic.
Design We applied a systems approach to the qualitative analysis of semi-structured interviews on the cross-sector, organizational response to the COVID-19 pandemic. We analyzed transcribed interviews using conventional content analysis to synthesize key themes.
Setting Semi-structured interviews were conducted via secure, video-conferencing platform between October 2020 and January 2021.
Participants Forty-four state and local decision-makers representing organizations from nine sectors in North Carolina participated.
Main Outcome Measures We defined the decision landscape as including decision-maker roles, key decisions, and inter-relationships involved in producing community health.
Results Decision-maker roles were characterized by underlying tensions between balancing organizational mission with employee/community health and navigating organizational versus individual responsibility for reducing transmission. Key Decisions fell into several broad categories, including how to translate public health guidance into practice; when to institute, and subsequently loosen, public health restrictions; and how to address downstream social and economic impacts of public health restrictions. Lastly, given limited and changing information, as well as limited resources and expertise, the COVID-19 response required cross-sector collaboration, which was commonly coordinated by local health departments.
Conclusions By documenting the local, cross-sector decision landscape that formed in response to COVID-19, we illuminate the impacts different organizations may have on information/misinformation, prevention behaviors, and, ultimately, health. Public health researchers and practitioners must understand, and work within, this complex decision landscape when responding to COVID-19 and future community health challenges.
Competing Interest Statement
Dr. Swann reported receiving compensation from Georgia Institute of Technology and Zoetis, Inc. in the prior 12 months. No other disclosures were reported.
Funding Statement
This research was supported by the National Center for Advancing Translational Sciences (NCATS), National Institutes of Health, Grant No. UL1TR002489, and the Council of State and Territorial Epidemiologists and Centers for Disease Control Cooperative Agreement No. NU38OT000297. CBB is additionally supported by a NIH Cancer Care Quality Training Program grant, UNC-CH, Grant No. T32-CA-116339. Funders did not have any role in the study design; collection, management, analysis, and interpretation of the data; writing of the manuscript; or the decision to submit the report for publication.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was determined to be exempt from review by the UNC Institutional Review Board (#20-2087).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Funding: This research was supported by the National Center for Advancing Translational Sciences (NCATS), National Institutes of Health, Grant No. UL1TR002489, and the Council of State and Territorial Epidemiologists and Centers for Disease Control Cooperative Agreement No. NU38OT000297. CBB is additionally supported by a NIH Cancer Care Quality Training Program grant, UNC-CH, Grant No. T32-CA-116339. Funders did not have any role in the study design; collection, management, analysis, and interpretation of the data; writing of the manuscript; or the decision to submit the report for publication.
Conflicts of Interest and Sources of Funding: Dr. Swann reported receiving compensation from Georgia Institute of Technology and Zoetis, Inc. in the prior 12 months. No other disclosures were reported.
Data Availability
Data produced in the present study are available upon reasonable request to the authors.
